http://www.fda.gov/cder/drug/advisory/elidel_protopic.htm
Center for Drug Evaluation and Research, U.S. Food and Drug Administration
The FDA is issuing a public health advisory to inform healthcare providers and patients about a potential cancer risk from use of Elidel (pimecrolimus) and Protopic (tacrolimus), products that are applied to the skin for the treatment of atopic dermatitis (eczema).